The Priority Review

The stream · Daily digest

The stream: Friday, October 30, 2026

8 briefs from ClinicalTrials.gov, the Federal Register and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Regulation · 4

  1. CMS final rule clarifies oversight of Organ Procurement Organizations

    The Centers for Medicare & Medicaid Services published a final rule that clarifies recertification, competition, and appeals processes for Organ Procurement Organizations. The rule defines unsound medical practices and requires OPOs to have QAPI programs to monitor adverse events.

    Source: CMS fact sheet, October 30, 2026

  2. PRAC starts review of Deanxit and human normal immunoglobulin safety signal

    PRAC has begun a review of Deanxit, a fixed-dose combination for depression and anxiety, after reports of serious neurological and psychiatric side effects. PRAC also started a review of a safety signal concerning increased reporting of hypersensitivity reactions associated with specific batches of human normal immunoglobulin medicines, including Flebogamma DIF, Yimmugo and Gamunex that have been withdrawn.

    Source: EMA news release, October 30, 2026

  3. FDA releases revised draft guidance on drug delivery device performance

    The FDA announced the availability of a revised draft guidance published October 30, 2026. The guidance replaces the draft guidance announced July 1, 2024 and provides recommendations for development and organization of device drug-delivery performance information.

    Source: Federal Register notice, October 30, 2026

  4. FDA classifies radiology software for fibrotic lung disease as class II

    The FDA finalized an order classifying the radiology software for referral of findings related to fibrotic lung disease as class II with special controls that will be part of the codified language for classification. The agency said the classification provides reasonable assurance of safety and effectiveness and may enhance patients' access to beneficial innovative devices by reducing regulatory burdens.

    Source: Federal Register rule, October 30, 2026

Clinical trials · 3

  1. Boehringer Ingelheim registers Phase III trial of verducatib in COPD

    The AIRWARD Study plans to enroll 1800 participants with COPD and plans to start on March 10, 2027. It evaluates whether verducatib reduces flare-ups and improves lung function compared with placebo over up to 1.5 years.

    Source: ClinicalTrials.gov registry record, October 30, 2026

  2. Hoffmann-La Roche posts results of Phase III crovalimab study in aHUS

    Results for the Phase III, single-arm study of crovalimab in adult and adolescent patients with atypical hemolytic uremic syndrome were first posted on ClinicalTrials.gov on October 30, 2026, after enrolling 83 participants. The study, which began on October 22, 2021, reached primary completion on October 9, 2025.

    Source: ClinicalTrials.gov results record, October 30, 2026

  3. PROSpect trial finds no difference in ventilator-free days with prone positioning or HFOV

    The PROSpect phase 3 trial, enrolling 424 of 600 planned patients, found no significant difference in ventilator-free days between prone and supine positioning (median 17·9 vs 17·4 days) or between HFOV and conventional ventilation (17·3 vs 18·0 days). The authors reported more frequent airway obstruction and immobility-related pressure injuries with prone positioning and more haemodynamic instability with HFOV, concluding that routine use of these strategies is not recommended.

    Source: PubMed record of a Phase III journal article, October 29, 2026

Approvals · 1

  1. FDA approves first plasmid DNA-based immunotherapy for adults with RRP

    The FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV. In an open-label multicenter trial of 32 adults, 27% of patients who had at least three baseline surgeries did not require any surgery during the first year after treatment.

    Source: FDA approval notification, October 30, 2026